Name: Prediction of Red Blood Cell Antibody Significance Using the Monocyte-Macrophage Assay (Video) | JoVE Journal
Uploaded: 2025-02-07T14:40:00.000+00:00
Duration: 11 min 27 s
Description: Discover the monocyte-macrophage assay for predicting red blood cell antibody significance in transfusion medicine. This enhanced method offers greater sensitivity than traditional MMA for improved clinical safety.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work is supported and funded by the Canadian Blood Services Centre for Innovation in Toronto, ON. Research is performed at the Keenan Research Centre for Biomedical Sciences at St. Michaels Hospital in Toronto, ON.

This research was performed in compliance with institutional guidelines for conducting ethical research involving human subjects. Ethics approval was granted from the Canadian Blood Services Research Ethics Board (REB), approval CBSREB#2023.008. All steps of this protocol are to be carried out in a biosafety cabinet under sterile conditions.

1. Isolation of PBMCs

<ol>
	<li>Obtain whole human blood from a donor in an ACD tube. Store the blood at room temperature (18 &#176;C&#8211;22 &#176;C) for up to 36 h.</li>
	<li>Transfer the whole blood ACD tubes to 50 mL centrifuge tubes (a single 50 mL tube for every two ACD tubes). Add RPMI-1640 complete medium at room temperature to a final volume of 35 mL.</li>
	<li>Add 15 mL of room temperature density gradient medium to a new 50 mL tube. Carefully layer the diluted whole blood on top of the density gradient medium, minimizing mixing at the interface for optimal separation of blood.</li>
	<li>Centrifuge the layered mixture at 700 x g for 30 min with brakes OFF. The density gradient centrifugation will separate the mixture into the following layers from top to bottom: Plasma, Buffy coat (containing PBMCs), density gradient material, Granulocytes, and red blood cells.&#160;</li>
	<li>Aspirate and discard the majority of the top layer (plasma). Using a transfer pipette, carefully retrieve the buffy coat (PBMCs) layer, avoiding bringing any additional material. Transfer the retrieved PBMCs into a new 50 mL tube.</li>
	<li>Wash the isolated buffy coat layer 1x with pH 7.4 PBS solution for 10 min at 350 x g with full brakes ON.</li>
	<li>Use a 70 &#181;M cell strainer to eliminate debris or unwanted material from the PBMCs before transferring them to a 15 mL conical tube.&#160;Wash 2x with pH 7.4 PBS solution for 10 min at 350 x g with full brakes ON.</li>
	<li>Optional: Lyse any RBCs carried over with ACK lysis buffer. Add 5-10 mL of ACK lysis buffer, depending on pellet size, and incubate at room temperature for up to 3 min. After incubation, top up with pH 7.4 PBS and centrifuge for 10 min at 350 x g with full brakes ON and wash 1x. Perform this step if the number of RBCs is too high. 
	NOTE: It always is better to avoid the use of ACK for better results. Alternatively, water can be used to eliminate non-phagocytosed RBCs by incubating with water for no longer than 15 seconds, then immediately add 1X&#160;PBS to wash.</li>
	<li>Reconstitute PBMC pellet in 2-3 mL (use 0.5 mL per initial ACD tube) of RPMI-1640 complete medium. Count PBMCs with a hemocytometer after preparing a 1:1 mixture with trypan blue. Only counts cells not stained with trypan blue. Reconstitute PBMCs to 2 x 106 cells/mL in RPMI-1640 complete medium.</li>
</ol>
2. Culture of M1/M2 macrophages

<ol>
	<li>Day 0 seeding of monocytes
	<ol>
		<li>&#160;Prepare a 25 mL cell culture flask for each macrophage population. Add 5 mL of poly-D-lysine (50 mg/500 mL) to each and leave it in the hood for at least 1 h. Rinse the flask with PBS to get rid of the residual poly-D-lysine.</li>
		<li>Isolate PBMCs from Buffy coat or patient samples, as usual (see step 1).&#160;After a pellet of PBMCs was generated, resuspend it in 10 mL of pre-warmed RPMI-1640 complete medium.</li>
		<li>Determine the cell number and begin the monocyte isolation with the Monocyte isolation kit. To run the kit, use at least 50 x 106 cells.</li>
		<li>Resuspend the cells at 50 x 106 cells/mL in an isolation medium. According to the cell number obtained, use the purple (0.25-2 mL) or gray (0.5-8.5 mL) magnet recommended in the monocyte isolation kit.</li>
		<li>Follow the kit instructions and add the sample to the required propylene tube (5 mL or 14 mL). Add enrichment cocktail to sample at 50 &#181;L/mL of sample.</li>
		<li>Pipet up and down or vortex to mix the sample and then incubate at 2-8 &#176;C for 10 min in an ice bucket.&#160;Meanwhile, vortex magnetic particles for 30 s. After incubation, add magnetic particles to the sample: 100 &#181;L/ml of sample.</li>
		<li>Pipet up and down or vortex to mix the sample and then incubate at 2-8 &#176;C for 5 min.&#160;Top up with isolation medium to 2.5 mL or 10 mL, accordingly using a graded pipette.&#160;Pipette up and down 2x-3x to mix.&#160;</li>
		<li>Place the tube (without lid) into the magnet and incubate at room temperature for 2.5 min.&#160;Pick up the magnet and, in one continuous movement, invert the magnet and tube, pouring the cell suspension into a new tube, 5 mL or 14 mL.&#160;</li>
		<li>Resuspend cells in RPMI-1640 medium and count them. Do this step as soon as possible. Seed between 1 x 106 &#8211; 5 x 106 monocytes into each 25 mL flask previously precoated with poly-D-lysine. Bring the volume to 5 mL with RPMI-1640 if necessary.</li>
		<li>Incubate at 37 &#176;C, 5% CO2, for at least 2 h. Meanwhile, prepare M1 and M2 differentiation media. Prepare enough for Day 0 (10 mL) and Day 4 (2 mL) top-up. 
		NOTE: M1 differentiation medium: RPMI-1640 + 2.5 ng/mL GM-CSF; M2 differentiation medium: RPMI-1640 + 50 ng/mL M-CSF.</li>
		<li>After the incubation time, wash each flask 1x with PBS and 2x with complete RPMI-1640. Add 10 mL of differentiation medium to each flask according to the cell type to differentiate.&#160;</li>
		<li>Let cells differentiate for 6 days in the incubator at 37 &#176;C, 5% CO2. Due to evaporation, top up with differentiation medium on Day 4.</li>
	</ol>
	</li>
	<li>Day 4 - Top-up
	<ol>
		<li>Add 2 mL of each differentiation medium to the respective flask. Add medium directly to the flask.</li>
	</ol>
	</li>
	<li>Day 6 - Macrophage polarization
	<ol>
		<li>Prepare M1 and M2 polarization media.&#160;For M1 polarization media, prepare 5 mL of M1 polarization medium to add to the corresponding flask. The final concentrations should be 50 ng/mL IFN&#947;, 10 ng/mL LPS, and 2.5 ng/mL GM-CSF in RPMI-1640. The flask at the end will have 15 mL of total volume (10 mL already in + 5 mL to be added), do the calculations accordingly.</li>
		<li>For M2 polarization media, prepare 5 mL of M2 polarization medium to add to the corresponding flask. The final concentrations should be 20 ng/mL IL-4 and 50 ng/mL M-CSF in RPMI-1640. Note that the flask at the end will have 15 mL of total volume (10 mL already in + 5 mL to be added); do the calculations accordingly.</li>
		<li>Add 5 mL of M1 or M2 polarization medium to each flask.&#160;Let the macrophages polarize for at least 2 days and not more than 4 days in the incubator at 37 &#176;C, 5% CO2.</li>
	</ol>
	</li>
	<li>Day 8 - Harvest and flow cytometry
	<ol>
		<li>Before harvesting the M1 or M2 macrophages, collect the supernatant into 1.5 mL tubes for further use (if needed).&#160;Add 1 mL of cell detachment solution to the flask and leave it in the incubator at 37 &#176;C, 5% CO2 for 5 min.</li>
		<li>To stop the reaction, add 3 mL of complete RPMI-1640. Collect media into a 15 mL tube. Add 3 mL of complete RPMI-1640 to the flask and use a cell scraper to detach the cells from the bottom of the flask.</li>
		<li>Collect cells in a 15 mL tube. Place the flask under the microscope at 10x and watch the cells to ensure no more cells are attached to the bottom of the flask.</li>
		<li>Wash the cells in PBS 2x. Resuspend them in complete RPMI-1640 and count using the hemocytometer.</li>
		<li>To analyze the quality and quantity of M1/M2 macrophages, run a flow cytometry assay. Use 0.5 x 106 cells per tube and stain as follows: M1: CD80+ CCR7+ CD209-&#160;M2: CD206+ CD209+ CD80-. Gating strategy used in this assay: #1 Forward Scatter (FSC-A) vs. Side Scatter (SSC-A) Dot Plot, #2 Forward Scatter Height (FSC-H) vs. Forward Scatter Area (FSC-A) Dot Plot for Doublet Discrimination, #3 Side Scatter (SSC-A) vs. DAPI-A Dot Plot for Live/Dead Cell Discrimination, #4 Side Scatter (SSC-A) vs. Single Parameter Dot Plot or Histogram (i.e., SSC-A vs. FITC-A), #5 Double Parameter Dot Plot (i.e., FITC-A vs. APC-A).</li>
	</ol>
	</li>
</ol>
3. MMA using M1/M2 macrophages

<ol>
	<li>After obtaining the M1/M2 macrophages, count them using a hemocytometer in a 1:1 staining ratio with trypan blue. Reconstitute M1/M2 to 1 x 106 cells/mL in RPMI-1640 complete medium.</li>
	<li>Seed 400 &#956;L (400,000 cells) of cell suspension using a micropipette into each well of the 8-well chamber slide and incubate at 37 &#176;C, 5% CO2 for at least 1.5 h in a fully humidified tissue culture incubator. Each test should be performed using a minimum of triplicate wells.</li>
	<li>Opsonization of testing samples and RhD+ R2R2 red blood cells
	<ol>
		<li>Wash RhD+ R2R2 RBCs in pH 7.4 PBS 3x by centrifugating at 350 x g for 5 min each time. We prefer to use R2R2 RhD+ RBCs as our control due to it having a higher D-antigen density, but any RhD+ RBCs could be substituted. Opsonize the testing RBC sample (e.g., patient or donor) RBCs using antibodies of interest. Use a 5% RBC suspension by adding 15 &#956;L of packed RBCs to 300 &#956;L of antibody mixture. Opsonize the R2R2 RBCs with Anti-D by adding 15 &#181;L of packed R2R2 RBCs to 300 &#181;L of Anti-D antibody mixture (100 ng/mL).</li>
		<li>Incubate at 37 &#176;C, 5% CO2 for 1 h. Carry out intermittent reconstitution of&#160;RBCs settled at the bottom (e.g., vortex every 15 min).&#160;Wash opsonized RBCs with pH 7.4 PBS 3x by centrifugation at 350 x g for 5 min each time.</li>
		<li>To check for RBC opsonization, perform an indirect antiglobulin test (IAT). Add a secondary opsonizing anti-human antibody to the primary opsonizing antibody. Hemagglutination or clumping of RBCs can be observed within 30 s and interpreted as a successful opsonization13.</li>
		<li>Reconstitute washed opsonized RhD+ R2R2 RBCs in 1.25% (v/v) with RPMI-1640 complete medium. Add 1,200 &#956;L of medium to 15 &#956;L of RBCs to achieve 1.25% (v/v) per well.</li>
	</ol>
	</li>
	<li>Fc receptor-mediated phagocytosis
	<ol>
		<li>After the 1.5 h incubation of the M1/M2 macrophages, to allow these cells to adhere to the wells of the chamber slide, aspirate the supernatant medium and discard, following a gentle technique, ensuring the pipette tip only touches the corner of the wells. The macrophages should be adhered to the wells. Avoid touching the middle of the wells with the pipette tip.</li>
		<li>Gently wash wells 1x with pH 7.4 PBS. Add 400 &#956;L of the appropriate 1.25% (v/v) opsonized RBC mixture to each well of the triplicate. Incubate at 37 &#176;C, 5% CO2 for 2 h undisturbed.</li>
		<li>After incubation, prepare two beakers with 100 mL of pH 7.4 PBS in each one.</li>
		<li>Remove the 8-well chambers using the manufacturer&#8217;s adaptors. Dab off excess on a paper towel while keeping slides moist.</li>
		<li>Submerge the slide into the beaker with the discarded supernatants and wash it by moving it back and forth slowly (20-30 strokes) to remove any remaining non-phagocytosed RBCs.</li>
		<li>Then submerge the slide in the second beaker and wash slowly for 20-30 strokes more. Remove the slide from PBS and dab off the excess on a paper towel. Avoid touching the front of the chambers. At this point, dip the slide into water for 1 min to remove any adherent, non-phagocytosed RBCs, but it may not be necessary if you can distinguish phagocytosed from adherent RBCs. Air dry.</li>
		<li>Submerge the slides in 100% methanol for 45 s to fix them, and then air dry. Mount the slide using an in-house prepared mounting medium and add coverslips (24 x 75 mm). Allow it to dry overnight before quantification.&#160;</li>
	</ol>
	</li>
	<li>Quantification of phagocytosis
	<ol>
		<li>Using a phase contrast microscope, 40x objective lens, and a manual cell counter, quantify phagocytosis.</li>
		<li>With the help of two manual cell counters, one in each hand, count phagocytosed RBCs with one counter and the total number of monocytes/macrophages with the other. Count 300 monocytes/macrophages per well.</li>
		<li>Calculate the average phagocytic index (PI) per test (across triplicates) by dividing the number of phagocytosed RBCs by the number of total monocytes counted and multiplying by 100. Express the data as average PI &#177; standard error of the mean (SEM). 
		PI = (phagocytosed RBCs / 300 macrophages) x 100</li>
	</ol>
	</li>
</ol>

<ol><li>Tong, T. N., Branch, D. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+a+monocyte+monolayer+assay+to+evaluate+Fc%CE%B3+receptor-mediated+phagocytosis%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Use of a monocyte monolayer assay to evaluate Fcγ receptor-mediated phagocytosis.</a> J Vis Exp. (119), e55039(2017).</li>
<li>Tong, T. N., Cen, S., Branch, D. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+monocyte+monolayer+assay%3A+Past%2C+present+and+future%5BTitle%5D)+AND+%22Transfus+Med+Rev%22%5BJournal%5D)">The monocyte monolayer assay: Past, present and future.</a> Transfus Med Rev. 33 (1), 24-28 (2019).</li>
<li>Frias Boligan, K., Sandhu, G., Branch, D. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Methods+to+evaluate+the+potential+clinical+significance+of+antibodies+to+red+blood+cells%5BTitle%5D)+AND+%22Curr+Protoc%22%5BJournal%5D)">Methods to evaluate the potential clinical significance of antibodies to red blood cells.</a> Curr Protoc. 2 (8), e504(2022).</li>
<li>Lemay, A. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+first+case+of+severe+acute+hemolytic+transfusion+reaction+caused+by+anti-Sc2%5BTitle%5D)+AND+%22Transfusion%22%5BJournal%5D)">The first case of severe acute hemolytic transfusion reaction caused by anti-Sc2.</a> Transfusion. 58 (11), 2506-2512 (2018).</li>
<li>Tong, T. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+utility+of+a+monocyte+monolayer+assay+in+the+assessment+of+intravenous+immunoglobulin-associated+hemolysis%5BTitle%5D)+AND+%22Transfusion%22%5BJournal%5D)">The utility of a monocyte monolayer assay in the assessment of intravenous immunoglobulin-associated hemolysis.</a> Transfusion. 60 (12), 3010-3018 (2020).</li>
<li>Srivastava, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((SCAR%3A+the+high-prevalence+antigen+013.008+in+the+Scianna+blood+group+system%5BTitle%5D)+AND+%22Transfusion%22%5BJournal%5D)">SCAR: the high-prevalence antigen 013.008 in the Scianna blood group system.</a> Transfusion. 61 (1), 246-254 (2021).</li>
<li>Branch, D. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Potentially+clinically+significant+anti-Dib+identified+by+monocyte+monolayer+assay+before+transfusion%5BTitle%5D)+AND+%22Transfusion%22%5BJournal%5D)">Potentially clinically significant anti-Dib identified by monocyte monolayer assay before transfusion.</a> Transfusion. 61 (1), 331-332 (2021).</li>
<li>Italiani, P., Boraschi, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((From+monocytes+to+M1%2FM2+macrophages%3A+Phenotypical+vs.+functional+differentiation%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation.</a> Front Immunol. 5, 514(2014).</li>
<li>Mills, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((M1+and+M2+macrophages%3A+Oracles+of+health+and+disease%5BTitle%5D)+AND+%22Crit+Rev+Immunol%22%5BJournal%5D)">M1 and M2 macrophages: Oracles of health and disease.</a> Crit Rev Immunol. 32 (6), 463-488 (2012).</li>
<li>Atri, C., Guerfali, F. Z., Laouini, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Role+of+human+macrophage+polarization+in+inflammation+during+infectious+diseases%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Role of human macrophage polarization in inflammation during infectious diseases.</a> Int J Mol Sci. 19 (6), 1801(2018).</li>
<li>Bertani, F. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Classification+of+M1%2FM2-polarized+human+macrophages+by+label-free+hyperspectral+reflectance+confocal+microscopy+and+multivariate+analysis%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis.</a> Sci Rep. 7, 8965(2017).</li>
<li>Murray, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Macrophage+polarization%5BTitle%5D)+AND+%22Annu+Rev+Physiol%22%5BJournal%5D)">Macrophage polarization.</a> Annu Rev Physiol. 79, 541-566 (2017).</li>
<li>Cohn, C., Delaney, M., Johnson, S. T., Katz, L. M., Schwartz, J. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aCohn%2C+C+%22Technical+Manual%22">Technical Manual</a>. , 21st Ed, American Association for the Advancement of Blood and Biotherapeutics. Maryland, USA. (2023).</li>
</ol>

The authors have nothing to disclose.

To ensure the method&#8217;s success, one must adhere to the following critical steps: 1) successful M1/M2 polarization, 2) generation of the macrophage layer and RhD+ control 3) quantification of phagocytic index. While our methods state to use isolated monocytes for the cell culture, PBMCs may be used, but we recommend using purified&#160;monocytes. It is known that PBMCs contain various cell types, with these cells secreting multiple different cytokines and mediating factors. This may have an impact on the differentia...

Predicting transfusion reactions remains a significant challenge in the field of transfusion medicine. Over the past 4 decades, the monocyte-monolayer assay (MMA), pioneered by Tong and Branch1,2, has served as a valuable in vitro cellular assay for predicting the clinical outcome of hemolysis in blood transfusion patients1. Indeed, this assay has been instrumental in distinguishing between clinically significant and insignificant red blood cell (RBC) antibodies2. While monocytes have traditionally been the standard leukocyte used in this assay, our research aims to explore the potential benefits of using monocyte-derived macrophages as an alternative. These cells may enhance the assays&#8217; ability to assess the clinical relevance of red cell alloantibodies.
In the historical MMA, monocytes, which are the precursors to macrophages, the immune cells responsible for the clearance and destruction of red blood cells during an adverse transfusion reaction, are introduced in an in vitro assay along with RBCs and antibodies1,2,3,4,5,6,7. Phagocytosis is then assessed visually by counting phagocytosed RBCs within monocytes. A phagocytic index (PI) of &#60; 5 phagocytosed RBCs per 100 monocytes counted indicates the patient is at a reduced risk of experiencing an adverse transfusion reaction, and the antibody is deemed clinically insignificant4,5,6,7. Preliminary experiments demonstrate using peripheral blood-derived monocytes may not be ideal for determining clinical significance as they have a lower phagocytic capacity than activated monocytes and certain macrophages.
Monocytes are a subset of cells found in the blood, spleen, and bone marrow and account for 10% of the total leukocytes in humans8. These cells typically circulate for 1-2 days before being recruited by different tissues, where they go on to differentiate into macrophages8. This typically happens during hematopoiesis, in which the bone marrow produces monocytes that are released into circulation to become tissue macrophages that reside in the spleen and the liver2. Known as the first line of defense against foreign pathogens, macrophages are large phagocytic mononuclear cells that play a role in adaptive and innate immunity9. Among the intricate and complex roles of the immune system, understanding and characterizing macrophage phenotypes presents a formidable challenge that is yet to be fully understood. Over the past two decades, the notion of macrophage polarization has garnered increasing recognition, with recent studies employing the use of single-cell RNA sequencing to discern the spectrum in which these macrophages exist.
Classically activated M1 and M1-like macrophages arise in inflammatory environments dominated by Toll-like receptors (TLRs)10. These cells may be involved in autoimmune diseases and arteriosclerosis and present surface markers such as MHC-II, CD80, and CD8611,12. Anti-inflammatory M2 and M2-like macrophages are found in environments dominated by Th2 responses, lack expression of CD80, and present surface markers such as CD209 and CD20611,12. M1/M2 macrophages may be cultured in vitro from peripheral blood mononuclear cells, with lipopolysaccharide (LPS) and cytokines such as GM-CSF and IFN&#947; (M1) and M-CSF and IL-4 (M2) stimulating their polarization10,12.
This manuscript and associated studies aim to demonstrate that M2 macrophages exhibit increased sensitivity for phagocytosis compared to M1 macrophages and monocytes. Investigating the phagocytic activity of M1/M2 macrophages versus monocytes in the context of red cell alloantibodies and transfusion medicine is an area that is yet to be explored. Here, we describe current ongoing work for the generation of M1/M2 macrophages and compare the classic monocyte monolayer assay (MMA) to the novel monocyte-macrophage assay, using the acronym M-MA to distinguish this macrophage assay from the monocyte assay, to improve the predictive value of in vitro phagocytosis assays.

<table><tbody><tr><td>1X PBS, pH 7.4, without Ca2+/Mg2+</td><td>Wisent Bioproducts&amp;nbsp;</td><td>311-425-CL</td><td>Store at 4 degrees or room temperauture&amp;nbsp;</td></tr><tr><td>AccutaseTM</td><td>STEMCELL Technologies&amp;nbsp;</td><td>7920</td><td>Cell detachment solution</td></tr><tr><td>ACK Lysis Buffer&amp;nbsp;</td><td>STEMCELL Technologies&amp;nbsp;</td><td>07850, 07800</td><td>Store at 4 degrees</td></tr><tr><td>Anti-Human Globulin</td><td>NOVACLONE, Immunocor.&amp;nbsp;</td><td>N/A</td><td>NOVACLONE Anti-igG for IAT testing&amp;nbsp;</td></tr><tr><td>Anti-Rh(D) (WinRho. SDF CDN)</td><td>Saol Therapeutics&amp;nbsp;</td><td>1003092</td><td>Any commerical source of Rh immune globin will suffice&amp;nbsp;</td></tr><tr><td>Cell Scraper</td><td>UofT Medstore</td><td>83.395</td><td>cell detachement&amp;nbsp;</td></tr><tr><td>Cell Strainer 70uM nylon</td><td>Falcon</td><td>352350</td><td>filter of cells&amp;nbsp;</td></tr><tr><td>Chamber slide Nunc. Lab-TekTM II with Cover, RS Glass Slide Sterile&amp;nbsp;</td><td>Thermo Fisher Scientific&amp;nbsp;</td><td>154534</td><td>chamber slides for MMA&amp;nbsp;</td></tr><tr><td>Coverslips&amp;nbsp;</td><td>VWR</td><td>48393-081</td><td>24 x 50 mm</td></tr><tr><td>Cytiva Ficoll Paque Plus, density 1.077 g/L</td><td>Thermo Fisher Scientific&amp;nbsp;</td><td>17-1440-03</td><td>sepeation of PBMCS from whole blood; density gradient medium</td></tr><tr><td>Elvanol Mounting Medium</td><td>N/A</td><td>N/A</td><td>Dulbecco&amp;rsquo;s PBS (D-PBS) without Ca2+/Mg2+, 15% (w/v) polyvinyl resin, and 30% (v/v) glycerine.</td></tr><tr><td>Fresh whole blood (ACD tube) or Buffy coat</td><td>Canadian Blood Services</td><td></td><td>May rest at room tempruatre for up to 36 hours&amp;nbsp;</td></tr><tr><td>Human Recombinant GM-CSF</td><td>STEMCELL Technologies&amp;nbsp;</td><td>78015.1</td><td>Cytokine for polarization of M1 macrophages</td></tr><tr><td>Human Recombinant IFN-gamma</td><td>STEMCELL Technologies&amp;nbsp;</td><td>78020</td><td>Cytokine for polarization of M1 macrophages</td></tr><tr><td>Human Recombinant IL-4</td><td>STEMCELL Technologies&amp;nbsp;</td><td>78045.1</td><td>Cytokine for polarization of M2 macrophages</td></tr><tr><td>Human Recombinant M-CSF</td><td>STEMCELL Technologies&amp;nbsp;</td><td>78057.1</td><td>Cytokine for polarization of M2 macrophages</td></tr><tr><td>ID-CellStab</td><td>Bio-Rad</td><td>005650 05740</td><td>RBC cell storage/stabilization solution&amp;nbsp;</td></tr><tr><td>Isolation Medium&amp;nbsp;</td><td>N/A</td><td>N/A</td><td>PBS Ca2+ and Mg2+ free + FBS 2% + 1mM EDTA</td></tr><tr><td>Lipopolysaaracide (LPS)</td><td>Sigma Aldrich</td><td>L3024-5MG</td><td>Cytokine for polarization of M1 macrophages</td></tr><tr><td>Methanol (100%)</td><td>N/A</td><td>N/A</td><td>Fixing of slides&amp;nbsp;</td></tr><tr><td>Monocyte Isolation Kit STEM-cells EasySep Human Monocyte Enrichment Kit without CD16 Depletion&amp;nbsp;</td><td>STEMCELL Technologies&amp;nbsp;</td><td>19058</td><td>Isolation of monocytes from PBMCs</td></tr><tr><td>Poly-D-ysine&amp;nbsp;</td><td>UofT Medstore&amp;nbsp;</td><td>P6407</td><td>Cell attachment solution&amp;nbsp;</td></tr><tr><td>Rh(D) positive R2R2 RBCs</td><td>Canadian Blood Services</td><td>N/A</td><td>Also commerically avaiable</td></tr><tr><td>RPMI-1640</td><td>Wisent Bioproducts&amp;nbsp;</td><td>350-000-CL</td><td>supplemented with 10% heat-inactivated FBS,1 mM GlutaMAX supplement, 1 mM HEPES, and 1%penicillin/streptomycin. Store at 4 degrees.&amp;nbsp;</td></tr><tr><td>Trypan Blue solution&amp;nbsp;</td><td>Thermo Fisher Scientific&amp;nbsp;</td><td>15250061</td><td>Cell counting solution&amp;nbsp;</td></tr></tbody></table>

prediction of red blood cell antibody significance using the monocyte-macrophage assay

Prediction of Red Blood Cell Antibody Significance Using the Monocyte-Macrophage Assay

Derived from monocytes in the bone marrow, macrophages are large, innate immune cells that play a major role in clearing dead cells, debris, tumor cells, and foreign pathogens. The phagocytic capacity of monocytes versus macrophages is a concept that is not well understood. Here, we aim to examine a difference in the phagocytosis of monocytes versus macrophages, specifically M1/M2 macrophages, against various opsonized red cells using a modified and updated version of the established monocyte monolayer assay (MMA). Peripheral blood mononuclear cells (PBMCs) were isolated from donor buffy coats. Using purified monocytes, inflammatory M1 and anti-inflammatory M2 macrophages were produced by in vitro culture and polarization. M1/M2 cells were harvested and used in an MMA-like assay, which we refer to as the M-MA, to decipher clinically significant phagocytosis of various red cell antibodies. A phagocytic index (PI) &#62; 5 was deemed clinically significant phagocytosis with the use of monocytes. A phagocytic index (PI) &#62; 12 was deemed clinically significant phagocytosis with the use of M1/M2 macrophages. M2 macrophages demonstrate an increased ability to phagocytose opsonized RBCs compared to monocytes and M1s. The same weak antibody (anti-S) yields significant phagocytosis with only M2 macrophages (PI=43) but not M1s (PI=2) or monocytes (PI=0), and this was demonstrated repeatedly using various antibodies. The use of M2 macrophages instead of monocytes may allow for more accurate results as these cells are more phagocytic, offering further clinical relevance to the assay. Further studies with different antibodies to red blood cells, including validation of the monocyte-macrophage assay (M-MA) with antibodies having known clinical significance, may show the M-MA&#160;more useful to help predict clinically significant red cell alloantibodies and transfusion reactions. This method will advance the field of transfusion medicine and immunology.

The results in Figure 1 are consistent with the literature and indicate a successful polarization of macrophages from their M0 state to their subsequent M1/M2 state. M1 and M2 macrophages were cultured for 8 days (6 days with growth factors and 2 days of polarization), and anti-D or anti-k opsonized RBCs were tested (Figure 2). M2 macrophages demonstrate a high phagocytic index compared to M1s with RBCs opsonized by either anti-D (control) or an...

We have developed enhancements and updated methods for the existing monocyte-monolayer assay (MMA), in which macrophages are used to help better predict the clinical relevance of red cell alloantibodies in transfusion medicine and immunology. This assay is named the monocyte-macrophage assay (M-MA).

Derived from monocytes in the bone marrow, macrophages are large, innate immune cells that play a major role in clearing dead cells, debris, tumor cells, ...

prediction-red-blood-cell-antibody-significance-using-monocyte

Research

JoVE Journal

Immunology and Infection

This video showcases a monocyte monolayer assay utilizing primary monocytes from peripheral blood to assess Fcγ receptor-mediated phagocytosis with poly D antibody-opsonized R2R2 red blood cells.

An Assay for Studying Fc&#947; Receptor-Driven Phagocytosis in Monocyte Monolayers

Monocyte-derived macrophages are important cells of the innate immune system. Here, we describe an easy to use in vitro model to generate these cells. Using gradient centrifugation, negative bead isolation and specific cell culture conditions, monocyte-derived macrophages can be generated for phenotypic and functional studies.

An In vitro Model to Study Heterogeneity of Human Macrophage Differentiation and Polarization

This protocol describes the use of whole-cell MALDI-TOF mass spectrometry on eukaryotic cells. Here, we illustrate the accuracy of this technique by analyzing the multiple activation states of macrophages in response to their microenvironment.

Whole-cell MALDI-TOF Mass Spectrometry is an Accurate and Rapid Method to Analyze Different Modes of Macrophage Activation

Here we describe two assays for measuring complement activation induced by antibodies against red blood cells. The major advantage over the current assays is their quantitative and easy-to-interpret nature.

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

We present a simple and efficient protocol for the generation of human macrophages. Buffy coats are processed by double density gradient centrifugation and isolated monocytes are then differentiated to macrophages in Teflon-coated cell culture bags. This maximizes macrophage yields and facilitates cell harvesting for subsequent experiments.

Isolation of Human Monocytes by Double Gradient Centrifugation and Their Differentiation to Macrophages in Teflon-coated Cell Culture Bags

The monocyte monolayer assay (MMA) is an in vitro assay that utilizes isolated primary monocytes obtained from mammalian peripheral whole blood to evaluate Fcγ receptor (FcγR)-mediated phagocytosis.

Use of a Monocyte Monolayer Assay to Evaluate Fc&#947; Receptor-mediated Phagocytosis

This protocol provides an analysis of the macrophage subpopulations in the adult mouse central nervous system by flow cytometry and is helpful for the study of multiple markers expressed by these cells.

Analysis of Microglia and Monocyte-derived Macrophages from the Central Nervous System by Flow Cytometry

Here we present a protocol for characterizing monocyte subsets by whole blood flow cytometry. This includes outlining how to gate the subsets and assess their expression of surface markers and giving an example of the assessment of the expression of M1 (inflammatory) and M2 markers (anti-inflammatory).

Characterization of Human Monocyte Subsets by Whole Blood Flow Cytometry Analysis

Here we present a protocol to quantify the chemotactic activity of blood monocytes in mouse models, to assess the effects of nutritional, pharmacological and genetic interventions on blood monocyte and to characterize the blood monocytes derived macrophages in mouse models using monocyte-chemoattractant protein-1 (MCP-1)-loaded basement membrane-derived gel plugs.

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages

The use of cytokine release assay reference reagents allows for more reproducible and standardized in vitro safety profiles of immunotherapeutic monoclonal antibodies. Here we describe how cytokine release assays can be used alongside a reference reagent panel to predict the safety of some therapeutic monoclonal antibodies.

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Monocytes and macrophages are very plastic and reprogrammable immune cells crucial for health and disease. They sense and respond to a broad range of stimuli by adopting specific differentiation programs and phenotypes. We have standardized an in-vitro model to study macrophage polarization and reprogramming, providing a valuable tool for research.

Reprograming Model of Human Monocyte-derived Macrophages for In-vitro Assays

Discover the monocyte-macrophage assay for predicting red blood cell antibody significance in transfusion medicine. This enhanced method offers greater sensitivity than traditional MMA for improved clinical safety.

Prediction of Red Blood Cell Antibody Significance Using the Monocyte-Macrophage Assay

Explore More Videos